Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Jenner

Showing results (151-160 of 177) with videos related to

Pageof 18
Sort By:
Clinical Neuropharmacology|June 15, 2006
Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primatesLance A Smith, Michael J Jackson, Louisa Johnston, et al.
Experimental Neurology|October 16, 2007
The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primatesMohammed Zubair, Michael J Jackson, Kayhan Tayarani-Binazir, et al.
European Journal of Pharmacology|August 28, 2014
The H3 receptor agonist immepip does not affect l-dopa-induced abnormal involuntary movements in 6-OHDA-lesioned ratsMaria Papathanou, Peter Jenner, Mahmoud Iravani, et al.
The European Journal of Neuroscience|September 30, 2005
Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesiaMahmoud M Iravani, Sergio Costa, Ghassan Al-Bargouthy, et al.
Bioorganic & Medicinal Chemistry Letters|August 27, 2013
Design, synthesis and biological evaluation of peptide derivatives of L-dopa as anti-parkinsonian agentsTao Zhou, Robert C Hider, Peter Jenner, et al.
Plos One|May 19, 2017
Altered detrusor contractility in MPTP-treated common marmosets with bladder hyperreflexiaSara Pritchard, Michael J Jackson, Atsuko Hikima, et al.
Plos One|July 25, 2017
Magnetic resonance imaging and tensor-based morphometry in the MPTP non-human primate model of Parkinson's diseaseMichel Modo, William R Crum, Madeline Gerwig, et al.
European Journal of Medicinal Chemistry|July 22, 2010
Design, synthesis and biological evaluation of L-dopa amide derivatives as potential prodrugs for the treatment of Parkinson's diseaseTao Zhou, Robert C Hider, Peter Jenner, et al.
Translational Neurodegeneration|October 13, 2022
Why do 'OFF' periods still occur during continuous drug delivery in Parkinson's disease?Silvia Rota, Daniele Urso, Daniel J van Wamelen, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 22, 2007
Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosetsRegina Katzenschlager, Michael J Jackson, Sarah Rose, et al.
Pageof 18

Showing results (151-160 of 177) with videos related to

Sort By:
Pageof 18
Clinical Neuropharmacology|June 15, 2006
Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primatesLance A Smith, Michael J Jackson, Louisa Johnston, et al.
Experimental Neurology|October 16, 2007
The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primatesMohammed Zubair, Michael J Jackson, Kayhan Tayarani-Binazir, et al.
European Journal of Pharmacology|August 28, 2014
The H3 receptor agonist immepip does not affect l-dopa-induced abnormal involuntary movements in 6-OHDA-lesioned ratsMaria Papathanou, Peter Jenner, Mahmoud Iravani, et al.
The European Journal of Neuroscience|September 30, 2005
Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesiaMahmoud M Iravani, Sergio Costa, Ghassan Al-Bargouthy, et al.
Bioorganic & Medicinal Chemistry Letters|August 27, 2013
Design, synthesis and biological evaluation of peptide derivatives of L-dopa as anti-parkinsonian agentsTao Zhou, Robert C Hider, Peter Jenner, et al.
Plos One|May 19, 2017
Altered detrusor contractility in MPTP-treated common marmosets with bladder hyperreflexiaSara Pritchard, Michael J Jackson, Atsuko Hikima, et al.
Plos One|July 25, 2017
Magnetic resonance imaging and tensor-based morphometry in the MPTP non-human primate model of Parkinson's diseaseMichel Modo, William R Crum, Madeline Gerwig, et al.
European Journal of Medicinal Chemistry|July 22, 2010
Design, synthesis and biological evaluation of L-dopa amide derivatives as potential prodrugs for the treatment of Parkinson's diseaseTao Zhou, Robert C Hider, Peter Jenner, et al.
Translational Neurodegeneration|October 13, 2022
Why do 'OFF' periods still occur during continuous drug delivery in Parkinson's disease?Silvia Rota, Daniele Urso, Daniel J van Wamelen, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 22, 2007
Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosetsRegina Katzenschlager, Michael J Jackson, Sarah Rose, et al.
Pageof 18